Login to Your Account



Insomnia

Sleeper data: Early stage efficacy, plus plenty of genes to explore

By Brian Orelli
Staff Writer

Monday, February 12, 2018

Despite being the second most prevalent mental disorder with a third of the general population reporting insomnia complaints and 10 percent meeting the strict definition of insomnia disorder, the treatment options for the disease are lacking. Considering that many treatments lead to tolerance and dependence and the potential for morning sedation, drugs using new mechanisms of action are sorely needed.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription